Event Date
Event Date
Location
https://youtu.be/NtR4qL1Zjeg
Link to a Map
https://youtu.be/NtR4qL1Zjeg
Hunter Land Vice President, Translational Research, Biopharmaceutical Research Company
This talk will provide an overview of the current state of active pharmaceutical ingredients (APIs) in the cannabinoid development industry. The speaker will discuss the key considerations for developing APIs for cannabinoid-based drugs, including the challenges and opportunities in the field, as well as the regulatory and intellectual property landscape. Attendees will gain insights into the strategic considerations for developing APIs for cannabinoid-based drugs, and learn about the latest trends and innovations in this rapidly evolving field.
Abstract: The recent legalization of cannabis in several states and the increasing acceptance of “medical marijuana” have led to a growing interest in the development of cannabinoid-based drugs. However, the development of APIs for these drugs presents unique challenges and opportunities. This talk will explore the key considerations for developing APIs for cannabinoid-based drugs, including the regulatory landscape, intellectual property considerations, formulations optimization, and the challenges of creating stable and consistent formulations. The speaker will also discuss the latest trends and innovations in the field, including the use of synthetic and biosynthetic cannabinoids, and the development of new delivery methods. Attendees will gain a deeper understanding of the strategic considerations involved in the development of APIs for cannabinoid-based drugs, and be better equipped to navigate the rapidly evolving landscape of this exciting field.
Hunter Land, PhD, MS: Is Vice President of Research at Biopharmaceutical Research Company, one of the few DEA Schedule I, FDA compliant cannabinoid research and development companies. He has 20 years of R&D expertise across 25 different indications, as well as 12 years of cannabinoid-focused research. As an expert in the field of cannabinoid science, he has developed a pipeline of discovery work on over 20 novel cannabinoids and terpenes. Previously, Dr. Land acted as the Sr. Scientific Director, Director of Cannabinoid Research, and scientific spokesperson at Canopy Growth Corporation, the world’s largest cannabis producer. Most notably, he was GW Pharma's first full-time R&D employee in the US, where he played a critical role in the development of Epidiolex® (FDA-approved prescription CBD) and Sativex®, and co-authored multiple protocols for the treatment of refractory epilepsy (Dravet Syndrome and Lennox-Gastaut Syndrome), multiple sclerosis, and pain. Dr. Land has presented at over 50 scientific conferences, is a named inventor on six patent applications, and has over 20 publications. In addition, he has serves as a guest lecturer at the University of Wisconsin and the University of Colorado Skaggs School of Pharmacy, and has been featured in Forbes and Entrepreneur as a cannabinoid subject matter expert. Dr. Land also holds several other important positions, including Chief Scientific Officer for the National Hockey League Alumni/NEEKA Brain Health, Executive Board Member at Alterola Biotech, co-founder of the Cannabinoid Education Working Group, scientific board member of the Veterinary Cannabis Society, and member of the advisory board for the Council for Federal Cannabis Regulation.